Antibiotic Resistance in Gram-Negative Bacteria: The Threat from the Pink Corner, 2nd Edition

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1570

Special Issue Editors


E-Mail Website
Guest Editor
School of Health and Life Sciences, Teesside University, Middlesbrough TS1 3BX, UK
Interests: antibiotic resistance; molecular epidemiology of Gram negative pathogens; Acinetobacter and Pseudomonas
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Dept. of Medical Microbiology & Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia
Interests: molecular microbiology; mechanism of antibiotic resistance; gastric cancer; cancer immunology; research on infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This issue will cover antibiotic resistance mechanisms and advances in modern medicine from faecal microbiota transplant to the development of novel drug therapies targeting hospital-acquired as well as foodborne Gram-negative pathogens. Original articles and reviews are particularly welcome in this field which relate to Gram-negative bacteria in the ESKAPE group as well as WHO critical and high priority pathogens.

Dr. Bruno Silvester Lopes
Dr. Alfizah Hanafiah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gram-negative
  • pseudomonas
  • acinetobacter
  • campylobacter
  • helicobacter
  • klebsiella
  • enterobacteriaceae
  • arcobacter
  • phages
  • complementary alternative medicine
  • antimicrobial peptides
  • food security
  • hospital acquired infections
  • microbiome
  • gram negative pathogens
  • antibiotic resistance
  • virulence and other molecular mechanisms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 397 KiB  
Article
Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Cohort Study
by Thamer A. Almangour, Zakiyah Alkherb, Leen Ghonem, Mohammed Al Musawa, Abdullah Almohaizeie, Sara Almuhisen, Aminah Alharbi, Nader Damfu, Doaa Aljefri, Jeelan Alghaith, Awaly Alfozan, Ahlam Alghamdi, Ahmad Aljabri, Abdullah A. Alhifany, Mohammed Alessa and Yazed Saleh Alsowaida
Pharmaceuticals 2025, 18(1), 108; https://doi.org/10.3390/ph18010108 - 16 Jan 2025
Viewed by 1113
Abstract
Purpose: To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) P. aeruginosa infections. Method: This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients [...] Read more.
Purpose: To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) P. aeruginosa infections. Method: This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR P. aeruginosa infections. Outcomes were compared using multivariate logistic regression analysis. Result: Among the screened patients, 203 patients were included: 89 in the CAZ-AVI group and 114 in the colistin group. A total of 57% presented with pneumonia, 21% with bacteremia, and 61% were in the intensive care unit. The rate of clinical cure was significantly higher among patients who received CAZ-AVI (67% vs. 50%; OR, 2.07; 95% CI, 1.16–3.68). The rate of in-hospital mortality was numerically lower among patients who received CAZ-AVI (40% vs. 49%; OR, 0.58; 95% CI, 0.33–1.03). The rate of AKI was significantly lower among patients who received CAZ-AVI (15% vs. 43%; OR, 0.23; 95% CI, 0.11–0.45). Conclusion: CAZ-AVI was more effective in treating MDR P. aeruginosa infections and showed a better safety profile compared to colistin. Thus, CAZ-AVI could be a better alternative for treating MDR P. aeruginosa infections. Full article
Show Figures

Figure 1

Back to TopTop